| 特发性肺纤维化治疗药物的研究进展 |
| |
| 引用本文： | 徐冰珠,康建磊. 特发性肺纤维化治疗药物的研究进展[J]. 现代药物与临床, 2015, 30(7): 897-902 |
| |
| 作者姓名： | 徐冰珠 康建磊 |
| |
| 作者单位： | 1. 清华大学医院,北京,100084
2. 国家食品药品监督管理总局药品审评中心,北京,100038 |
| |
| 摘 要： | 特发性肺纤维化(IPF)是一种不可逆、进展性、致死性的慢性肺纤维化疾病,其进展较快,存活率较低,缺乏有效诊疗手段和治疗药物。近年来随着对其发病机制的了解,IPF治疗药物的开发也取得了一定进展。全球新批准并上市的治疗药物有吡非尼酮和尼达尼布,处于研发I、II期的有10多种,另外也有一些曾经有希望但已经不推荐用于IPF治疗的药物。
|
| 关 键 词： | 特发性肺纤维化 治疗药物 吡非尼酮 尼达尼布 |
| 收稿时间： | 2015-05-08 |
Research progress on drugs in treatment of idiopathic pulmonary fibrosis |
| |
| XU Bing-zhu and KANG Jian-lei. Research progress on drugs in treatment of idiopathic pulmonary fibrosis[J]. Drugs & Clinic, 2015, 30(7): 897-902 |
| |
| Authors: | XU Bing-zhu and KANG Jian-lei |
| |
| Affiliation: | Tsinghua University Hospital, Beijing 100084, China;Center for Drug Evaluation, CFDA, Beijing 100038, China |
| |
| Abstract: | Idiopathic pulmonary fibrosis (IPF) is a chronic pulmonary fibrosis disease with irreversible, progressive, and fatal phenomenon, characterized by rapid progression and high mortality. And there are lack of effective diagnostic methods and treatment drugs. Recently, with the understanding of its pathogenesis, IPF drug development have also made some progress. Pirfenidone and nintedanib are new drugs approved and listed, and there are more than ten IPF drugs under development. In addition, there are some hope for IPF treatment drugs, but now are not recommended. |
| |
| Keywords: | idiopathic pulmonary fibrosis therapeutic drugs pirfenidone nintedanib |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
| 点击此处可从《现代药物与临床》浏览原始摘要信息 |
|
点击此处可从《现代药物与临床》下载全文 |
|
